Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Beta-amyloid imaging in dementia

  • Chun, Kyung Ah (Department of Nuclear Medicine, Yeungnam University College of Medicine)
  • Received : 2017.10.22
  • Accepted : 2018.01.03
  • Published : 2018.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder associated with extracellular plaques, composed of amyloid-beta ($A{\beta}$), in the brain. Although the precise mechanism underlying the neurotoxicity of $A{\beta}$ has not been established, $A{\beta}$ accumulation is the primary event in a cascade of events that lead to neurofibrillary degeneration and dementia. In particular, the $A{\beta}$ burden, as assessed by neuroimaging, has proved to be an excellent predictive biomarker. Positron emission tomography, using ligands such as $^{11}C$-labeled Pittsburgh Compound B or $^{18}F$-labeled tracers, such as $^{18}F$-florbetaben, $^{18}F$-florbetapir, and $^{18}F$-flutemetamol, which bind to $A{\beta}$ deposits in the brain, has been a valuable technique for visualizing and quantifying the deposition of $A{\beta}$ throughout the brain in living subjects. $A{\beta}$ imaging has very high sensitivity for detecting AD pathology. In addition, it can predict the progression from mild cognitive impairment to AD, and contribute to the development of disease-specific therapies.

Keywords

References

  1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-44. https://doi.org/10.1056/NEJMra0909142
  2. Yoshiyama Y, Lee VM, Trojanowski JQ. Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry 2013;84:784-95. https://doi.org/10.1136/jnnp-2012-303144
  3. Won WY, Lee CU. Biomarkers for Alzheimer's dementia: focus on neuroimaging. Korean J Biol Psychiatry 2011;18:72-79. Korean.
  4. Villemagne VL, Dore V, Bourgeat P, Burnham SC, Laws S, Salvado O, et al. $A{\beta}$-amyloid and tau imaging in dementia. Semin Nucl Med 2017;47:75-88.
  5. Murphy MP, LeVine H 3rd. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis 2010;19:311-23. https://doi.org/10.3233/JAD-2010-1221
  6. Harper JD, Lansbury PT Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 1997;66:385-407. https://doi.org/10.1146/annurev.biochem.66.1.385
  7. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992;359:325-7. https://doi.org/10.1038/359325a0
  8. Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience 2001;105:99-107. https://doi.org/10.1016/S0306-4522(01)00169-5
  9. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003;62:1087-95. https://doi.org/10.1093/jnen/62.11.1087
  10. Pearson HA, Peers C. Physiological roles for amyloid beta peptides. J Physiol 2006;575:5-10. https://doi.org/10.1113/jphysiol.2006.111203
  11. Villemagne VL, Cappai R, Barnham KJ, Cherny RA, Opazo C, Novakovic KE, et al. The $A{\beta}$ centric pathway of Alzheimer's disease. In: Barrow CJ, Small DH, editors. Abeta peptide and Alzheimer's disease: celebrating a century of research. London: Springer; 2007. p. 5-32.
  12. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997;20:154-9. https://doi.org/10.1016/S0166-2236(96)01030-2
  13. Kim JS, Oh SJ, Moon DH. Molecular imaging in neurodegenerative diseases. J Korean Med Assoc 2009;52:151-67. Korean. https://doi.org/10.5124/jkma.2009.52.2.151
  14. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging betaamyloid pathology. JAMA 2011;305:275-83. https://doi.org/10.1001/jama.2010.2008
  15. Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011;68:1398-403. https://doi.org/10.1001/archneurol.2011.153
  16. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19. https://doi.org/10.1002/ana.20009
  17. Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006;67:1575-80. https://doi.org/10.1212/01.wnl.0000240117.55680.0a
  18. Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011;77:2034-42. https://doi.org/10.1212/WNL.0b013e31823b9c5e
  19. Lehmann M, Ghosh PM, Madison C, Laforce R Jr, Corbetta-Rastelli C, Weiner MW, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 2013;136:844-58. https://doi.org/10.1093/brain/aws327
  20. Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012;27:965-73. https://doi.org/10.1002/mds.25048
  21. Graff-Radford J, Boeve BF, Pedraza O, Ferman TJ, Przybelski S, Lesnick TG, et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain 2012;135:2470-7. https://doi.org/10.1093/brain/aws173
  22. Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013;80:85-91. https://doi.org/10.1212/WNL.0b013e31827b1a07
  23. Xia C, Dickerson BC. Multimodal PET imaging of amyloid and tau pathology in Alzheimer disease and non-Alzheimer disease dementias. PET Clin 2017;12:351-9. https://doi.org/10.1016/j.cpet.2017.02.005
  24. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275-83. https://doi.org/10.1016/j.neurobiolaging.2010.04.007
  25. Wang F, Gordon BA, Ryman DC, Ma S, Xiong C, Hassenstab J, et al. Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology 2015;85:790-8. https://doi.org/10.1212/WNL.0000000000001903
  26. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015;313:1924-38. https://doi.org/10.1001/jama.2015.4668
  27. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-65. https://doi.org/10.1093/brain/awp062
  28. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimers Dement 2013;9:e106-9. https://doi.org/10.1016/j.jalz.2013.06.001
  29. Bosscher L, Scheltens P. MRI of the medial temporal lobe for the diagnosis of Alzheimer's disease. In: Qizilbash N, editor. Evidence-based dementia practice. Osney Mead, Oxford; Malden, MA: Blackwell Science; 2002. p. 154-62.
  30. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 2008;49:390-8. https://doi.org/10.2967/jnumed.107.045385
  31. Arbizu J, Garcia-Ribas G, Carrio I, Garrastachu P, Martinez-Lage P, Molinuevo JL. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus. Rev Esp Med Nucl Imagen Mol 2015;34:303-13.
  32. Sanchez-Juan P, Ghosh PM, Hagen J, Gesierich B, Henry M, Grinberg LT, et al. Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology 2014;82:230-8. https://doi.org/10.1212/WNL.0000000000000032
  33. Barthel H, Sabri O. Clinical use and utility of amyloid imaging. J Nucl Med 2017;58:1711-7. https://doi.org/10.2967/jnumed.116.185017
  34. Masters CL, Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain 2006;129:2823-39. https://doi.org/10.1093/brain/awl251
  35. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-tomoderate Alzheimer's disease. N Engl J Med 2014;370:322-33. https://doi.org/10.1056/NEJMoa1304839
  36. Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces $A{\beta}$ plaques in Alzheimer's disease. Nature 2016;537:50-6. https://doi.org/10.1038/nature19323
  37. Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011;3:111-33.

Cited by

  1. Protective roles of isoastilbin against Alzheimer's disease via Nrf2-mediated antioxidation and anti-apoptosis vol.43, pp.3, 2018, https://doi.org/10.3892/ijmm.2019.4058
  2. Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring vol.22, pp.4, 2021, https://doi.org/10.3390/ijms22042110